glp-1 and gip receptor agonist Targeting GLP-1, & GCG in Obesity Type 2 Diabetes Research Beyond the pancreas: contrasting cardiometabolic
Description
Meanwhile, research published in May suggests a potential association between taking Wegovy (a GLP-1) and an increased chance of developing NAION
A baseline and follow-up eye exam ensures that ocular risk factors are balanced against systemic gains, the report states
[4] Due to the high demand for GLP-1 drugs in the U.S
Clin Transpl
8 Compared with placebo, once weekly tirzepatide significantly reduced the combined risk of cardiovascular death or worsening HF events (hospitalisation or an urgent hospital visit requiring intravenous therapy)
